Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Excellent trading update. Growing strongly with revenue up 50% plus and exciting outlook. Niche player in non-invasive cosmetic enhancement. Either go it alone or as a takeover target looks good for 2017 and beyond.
that was good ! see what happens to the sp today
odd to see the sells considering the news is expected to be good vol low considering news in a few trading days maybe people waiting for a very small better buy in ? all i can think of at moment lol
The full-year trading update next Tuesday should be good news given a forecast 40% sales growth for 2016 at the interims. The half year results stated: The Board is highly optimistic that there will be significant near and medium term operating leverage. The business is already close to break-even at the EBITDA level (pre US investment), yet anticipated sales growth is strong with very high marginal profitability as a result of high and rising gross margins and a relatively fixed operating cost base. The proof of the pudding is on 17th and the shares should start to reflect current prospects rather than low-margin legacy operations.
Many thanks for that, although I should have known this! I knew A was automated but stupidly never equated it to a "bot trade"
George Soros sits on 5% and Sinclair is promoting Perfectha in USA. Do I expect a $ bidder to appear??? Yep. All to do with timing and this hits all the buttons on exchange rates and prospects imo. SPH can go it nicely alone but a 60p a share bid from the States would seal it.
250k initial followed by machine-gun 500-600 shares purchased in succession. Methinks a bigger player has a buy order in for this cash rich niche aesthetics player. Would fit neatly into health/cosmetics portfolio of several old and one new player [Nestle]. This is a high barrier to entry, high profit margin business which is pretty recession-proof. Great buy with Sterling at near lows.
Hi blue/ on the share transactions an A indicates Automated Trade [bot-trade] - look at frequency and quantity; like machine-gun buying in packages as shares are available being mopped up.
How can one tell there is "an escalation in bot bids". Hope you don't mind me asking but I would not know where to look!
Automated buying in volume. Long overdue this is now moving strongly north. Massive potential in this specialist aesthetics business; cash in the bank and no debt. A very tasty morsel either alone or in the eyes of a bigger fish - must be getting noticed as I said before. It is an ideal fit for Nestle's expansion into health and beauty and that would spark a bid war. I note with interest he escalation in bot bids.
George Soros spent £9m in June 2014 taking his stake in aesthetics and skin care company Sinclair IS Pharma above 5 per cent by acquiring more stock at 32p a pop and also Sinclair would therefore be a perfect bolt-on for Nestle, which [also in summer 2014] acquired the rights to sell certain skin care products in the US and Canada from Valeant Pharmaceuticals, based in Quebec, for £840m cash. Add in the fact that Sinclair is now a lean and focused aesthetics business having divested its pharmaceuticals, and that it is cash-rich and debt-free............... looks a very interesting rise from recent lows given future prospects. DTR.
Healthy rise on good volume over past two days. Broken up through 20 and 50 mda's and outlook looks very promising for this focused aesthetics business. Deserves a rerate as debt-free, lots of cash and generating income in a high margin field. Neat.
Attractive value for niche operator. http://www.hardmanandco.com/docs/default-source/company-docs/sinclair-pharma-plc-documents/08.11.16-poised-for-a-long-term-uplift.pdf Valued at 60p on M+A activity in sector and 99p on prospects with 30-40% sales growth [most of which is in the bag at end Q3]. Cash in the bank and well-funded to cash breakeven next year. Good entry point imo pending news from USA and Brazil.
it was 27.50p to buy this morning ,looking good now
The shift to minimally invasive cosmetic surgery is gaining pace. Sinclair BoD had the foresight to put the company smack in the moddle of this growth area. Divested of the low margin business, with no debt and a nice cash pile the future looks very promising indeed. The current push into the US market gives a high possibility of a game-changer going into 2017. Definitely one to take an interest in at this stage in development. The confident presentation asses see the prospects well.
Chris Spooner presents at the Biotech Capital Conference https://www.youtube.com/watch?v=8ZCgwz_D_WI&feature=youtu.be
Sinclair Pharma plc Delivering strong growth, completed transformational US distribution deal, on track to meet full year guidance Sinclair Pharma plc (SPH.L), ("Sinclair", or the "Group", or the "Company") the international specialty pharma company, today announces its unaudited results for the six and twelve month periods ended 30 June 2016. Highlights - Reported revenues show significant growth reflecting strong in market sales and planned de-stocking in prior six month period. Group revenues increased 125% to GBP17.3 million compared to GBP7.7 million in the previous six month period o On track to meet guidance of 40% sales growth for calendar year 2016, pre Brazil consolidation and US Silhouette Soft(R) sales o Silhouette Soft(R) sales increased 94% to GBP6.2 million (GBP3.2 million for the previous six months) o Ellansé(R) sales increased 147% to GBP4.2 million (GBP1.7 million in the previous six months) o Perfectha(R) sales up 184% to GBP3.7 million (GBP1.3 million in the previous six months) o Sculptra(R) sales back on track, up 146% to GBP3.2 million (GBP1.5 million in the previous six months) o Distributor inventory levels remain normalised
And someone just bought 30! Do you think they missed the 2 in front of it? The SPH chart is discussed by Justin and Nicola Duke on vox today, next to clear is 28.6 apparently! GLA
And someone just bought 30! Do you think they missed the 2 in front of it? The SPH chart is discussed by Justin and Nicola Duke on vox today, next to clear is 28.6 apparently! GLA
15-Sep-16 RBC Capital Markets Outperform - 5,000.00 Reiteration Have just checked the SPH Broker Ratings. Now that would be a surprise!!!!
Someone who has 9770 shares maybe???
Who buys 230 shares at a time? That is really weird...
Great results today and future looking bright IMO: Group revenues increased 125% to £17.3 million compared to £7.7 million in the previous six month period o On track to meet guidance of 40% sales growth for calendar year 2016, pre Brazil consolidation and US Silhouette Soft® sales o Silhouette Soft® sales increased 94% to £6.2 million (£3.2 million for the previous six months) o Ellansé® sales increased 147% to £4.2 million (£1.7 million in the previous six months) o Perfectha® sales up 184% to £3.7 million (£1.3 million in the previous six months) o Sculptra® sales back on track, up 146% to £3.2 million (£1.5 million in the previous six months) Reshuffle of the board, consolidation of products all targeting a high growth business branching out globally including distribution network in US and Brazil (one of the top five global aesthetic markets). What’s not to like but of course sniff around and DYOR.
Can anyone explain to me y the trade I did today are not showing. I purchased four lots of 20000 share at around 35.92????
Wife of to be exact, there is a very close spread right now whatever that means. It's trying to rally except someone is also selling a lot, we will have to see who wins. If the RNS is anything to go by we should be moving up.